🔗 Shared analysis
All filings for SYMBIOTEC →
Symbiotec Pharmalab Q1 FY27 Earnings Call Transcript: Over 90% Revenue from Core API Segment
Symbiotec Pharmalab has submitted the transcript for its Q1 FY27 earnings conference call held on September 22, 2026. The management highlighted that over 90% of its current fiscal year revenues come from its core steroid and hormone API business, which is expected to grow in high single digits. The company is diversifying into high-margin biotech fermentation CDMO and complex injectables platforms, aiming for these new verticals to constitute more than 50% of revenue in 5-6 years. Furthermore, nearly 70% of FY26 revenues were derived from relationships older than 7 years across 200+ global customers.
Confidence: HIGH
What changedFiling of the official transcript for the maiden post-listing Q1 FY27 earnings conference call.
Why it mattersProvides management commentary on strategic diversification beyond core APIs into higher-margin CDMO and complex injectables platforms.
Core API revenue share (FY27E): >90%Long-term API revenue share target (5-6 yrs): <50%FY26 revenue from >7-year relationships: ~70%Active US DMFs / European CEPs: 44 / 25Q1 FY27 Revenue: ₹218.15 cr
📅 Short termLimited direct market impact as the transcript reflects information already discussed on the call held on September 22, 2026.
📈 Long termExpansion into CDMO and complex injectables targets higher industry benchmark margins (>35% EBITDA) and reduces reliance on the mature core API business.
⚠ Risk flags
- Execution and commercialization risks in newer CDMO and injectable verticals
- Dependency on partner regulatory filings (e.g., generic Premarin) outside direct company control
Key Highlights
Over 90% of current fiscal year annual revenue is estimated to come from the steroid hormones API business.
Nearly 70% of FY26 revenues came from clients with customer relationships exceeding 7 years.
Portfolio supported by 44 US DMFs and 25 European CEPs across 60 corticosteroid and hormone APIs.
Long-term guidance envisions new CDMO and injectables verticals reducing the core API revenue share to less than 50% in 5-6 years.
Industry peer benchmark EBITDA margins for complex CMO and injectables cited at above 35% with gross margins over 70%.
👀 What to Watch
Track the commercialization and revenue ramp-up in the biotech fermentation CDMO and complex injectables segments over upcoming quarters.
📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-14 18:27
330 analysed today
FollowTelegram
330
Today
150,769
All-time analysed
43,177
Positive
6,703
Negative
92,116
Neutral
8,705
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
1,000+ announcements match the current filters (relevance ≥ 5).
CEAT Q2 Consolidated Revenue Up 26% YoY to Rs 4,762 Cr; EBITDA Margin at 9.5%
CEAT reported Q2 FY26-27 consolidated revenue of Rs 4,762 crore, marking a 26% YoY increase driven by growth in premium segments. Consolidated net profit came in at Rs 112 crore, while EBITDA margin stood at 9.5% amid high raw material costs fueled by the West Asia conflict. Standalone net profit reached Rs 164 crore on revenue of Rs 4,548 crore (up 23% YoY). The company invested close to Rs 490 crore in capex during the quarter (~3% of TTM revenue) to expand high-utilization capacities and appointed Mr. Sumeet Narang as an Independent Director.
Confidence: HIGH
What changedCEAT declared its Q2 FY26-27 unaudited financial results and approved the appointment of Mr. Sumeet Narang as Non-Executive Independent Director for 5 years.
Why it mattersDemonstrates robust top-line momentum via premiumization and CAMSO inclusion, though ongoing commodity headwinds are compressing operating margins to single digits.
Consolidated Revenue: Rs 4,762 croreConsolidated Net Profit: Rs 112 croreConsolidated EBITDA Margin: 9.5%Quarterly Capex: close to Rs 490 croreQuarter Capex vs TTM Revenue: ~3.0%
📅 Short termMargins will likely face sustained pressure in Q3 as commodity costs remain elevated, but price hikes in H2 may partially mitigate this impact.
📈 Long termIntegration of the Camso business and premiumization across passenger car and 2-wheeler tyres support capacity absorption, though elevated debt from ongoing capex bears watching.
⚠ Risk flags
- Elevated raw material costs linked to geopolitical tensions in West Asia
- Increased debt levels driven by continuous capex of ~Rs 490 crore and dividend payouts
Key Highlights
Consolidated revenue up 26% YoY to Rs 4,762 crore in Q2
Consolidated net profit stood at Rs 112 crore with an EBITDA margin of 9.5%
Standalone revenue increased 23% YoY to Rs 4,548 crore with net profit of Rs 164 crore
Quarterly capex deployed at close to Rs 490 crore to expand capacities, driving up debt
Converted $24.5 million loan to Ceat OHT Lanka into Rs 234 crore equity
👀 What to Watch
Monitor commodity price trends and the management's planned calibrated price hikes in H2 to offset persistent input cost inflation.
CEAT Q2 Consolidated Revenue Up 26% YoY to Rs 4,762 Cr; EBITDA Margin at 9.5%
CEAT reported Q2 FY26-27 consolidated revenue of Rs 4,762 crore, marking a 26% YoY increase driven by growth in premium segments. Consolidated net profit came in at Rs 112 crore, while EBITDA margin stood at 9.5% amid high raw material costs fueled by the West Asia conflict. Standalone net profit reached Rs 164 crore on revenue of Rs 4,548 crore (up 23% YoY). The company invested close to Rs 490 crore in capex during the quarter (~3% of TTM revenue) to expand high-utilization capacities and appointed Mr. Sumeet Narang as an Independent Director.
Confidence: HIGH
What changedCEAT declared its Q2 FY26-27 unaudited financial results and approved the appointment of Mr. Sumeet Narang as Non-Executive Independent Director for 5 years.
Why it mattersDemonstrates robust top-line momentum via premiumization and CAMSO inclusion, though ongoing commodity headwinds are compressing operating margins to single digits.
Consolidated Revenue: Rs 4,762 croreConsolidated Net Profit: Rs 112 croreConsolidated EBITDA Margin: 9.5%Quarterly Capex: close to Rs 490 croreQuarter Capex vs TTM Revenue: ~3.0%
📅 Short termMargins will likely face sustained pressure in Q3 as commodity costs remain elevated, but price hikes in H2 may partially mitigate this impact.
📈 Long termIntegration of the Camso business and premiumization across passenger car and 2-wheeler tyres support capacity absorption, though elevated debt from ongoing capex bears watching.
⚠ Risk flags
- Elevated raw material costs linked to geopolitical tensions in West Asia
- Increased debt levels driven by continuous capex of ~Rs 490 crore and dividend payouts
Key Highlights
Consolidated revenue up 26% YoY to Rs 4,762 crore in Q2
Consolidated net profit stood at Rs 112 crore with an EBITDA margin of 9.5%
Standalone revenue increased 23% YoY to Rs 4,548 crore with net profit of Rs 164 crore
Quarterly capex deployed at close to Rs 490 crore to expand capacities, driving up debt
Converted $24.5 million loan to Ceat OHT Lanka into Rs 234 crore equity
👀 What to Watch
Monitor commodity price trends and the management's planned calibrated price hikes in H2 to offset persistent input cost inflation.
CRISIL Upgrades Piccadily Agro's Bank Debt to 'CRISIL A+/Stable/A1' on Rs 400 Cr Facilities
CRISIL Ratings has assigned and upgraded Piccadily Agro Industries' bank loan facilities of Rs 400 crore to 'CRISIL A+/Stable' for long-term and 'CRISIL A1' for short-term (previously IVR A/Stable and IVR A1 by Infomerics). The agency highlighted strong performance led by its flagship single malt brand 'Indri' and expanded distillery operations, projecting 50-60% revenue growth in FY27. Financial leverage is comfortable with gearing at 0.6x as of March 31, 2026, and interest coverage at 8.6 times in FY26. Total rated bank debt of Rs 400 crore represents approximately 35.2% of its TTM revenue of Rs 1,137 crore.
Confidence: HIGH
What changedCRISIL assigned and upgraded the company's bank loan rating to 'CRISIL A+/Stable/CRISIL A1' from Infomerics' 'IVR A/Stable/IVR A1' for Rs 400 crore bank facilities.
Why it mattersThe rating upgrade lowers borrowing costs, validates the ongoing operational turnaround from sugar to high-margin premium single malt spirits, and confirms a comfortable balance sheet with 0.6x gearing.
Total Bank Loan Facilities Rated: Rs 400 CroreRated debt vs TTM revenue: ~35.2%Projected FY27 Revenue Growth: 50–60%Reported Net Worth (March 2026): Rs 901 croreGearing (March 31, 2026): 0.6 times
📅 Short termPositive sentiment from an established tier-1 agency upgrade validating balance sheet strength and operational cash flow health.
📈 Long termReflects the company's structural shift toward luxury and premium spirits, underpinned by matured malt inventories and scaled distillery capacities that provide durable margin expansion.
⚠ Risk flags
- High working capital intensity driven by inventory aging requirements for single malts.
- Vulnerability to state-level liquor excise regulations and changes in ethanol procurement policies.
Key Highlights
Credit rating upgraded to CRISIL A+/Stable (Long Term) and CRISIL A1 (Short Term) across Rs 400 crore bank facilities.
CRISIL projects revenue growth of 50-60% in FY27 driven by recent capacity expansions and Indri single malt penetration.
Operating margins reached 22.5% in FY26 and are projected at 22-24% in FY27 as distillery revenue share hit 79%.
Gearing stood at ~0.6x as of March 31, 2026, with net worth at Rs 901 crore and interest coverage at 8.6 times.
👀 What to Watch
Track the ramp-up and excise approvals of the expanded Indri malt distillery (30 KLPD) and greenfield Chhattisgarh facility (200 KLPD) alongside working capital efficiency in upcoming quarterly results.
CEAT Q2 Consolidated Revenue Up 26% YoY to Rs 4,762 Cr; EBITDA Margin at 9.5%
CEAT reported Q2 FY26-27 consolidated revenue of Rs 4,762 crore, marking a 26% YoY increase driven by growth in premium segments. Consolidated net profit came in at Rs 112 crore, while EBITDA margin stood at 9.5% amid high raw material costs fueled by the West Asia conflict. Standalone net profit reached Rs 164 crore on revenue of Rs 4,548 crore (up 23% YoY). The company invested close to Rs 490 crore in capex during the quarter (~3% of TTM revenue) to expand high-utilization capacities and appointed Mr. Sumeet Narang as an Independent Director.
Confidence: HIGH
What changedCEAT declared its Q2 FY26-27 unaudited financial results and approved the appointment of Mr. Sumeet Narang as Non-Executive Independent Director for 5 years.
Why it mattersDemonstrates robust top-line momentum via premiumization and CAMSO inclusion, though ongoing commodity headwinds are compressing operating margins to single digits.
Consolidated Revenue: Rs 4,762 croreConsolidated Net Profit: Rs 112 croreConsolidated EBITDA Margin: 9.5%Quarterly Capex: close to Rs 490 croreQuarter Capex vs TTM Revenue: ~3.0%
📅 Short termMargins will likely face sustained pressure in Q3 as commodity costs remain elevated, but price hikes in H2 may partially mitigate this impact.
📈 Long termIntegration of the Camso business and premiumization across passenger car and 2-wheeler tyres support capacity absorption, though elevated debt from ongoing capex bears watching.
⚠ Risk flags
- Elevated raw material costs linked to geopolitical tensions in West Asia
- Increased debt levels driven by continuous capex of ~Rs 490 crore and dividend payouts
Key Highlights
Consolidated revenue up 26% YoY to Rs 4,762 crore in Q2
Consolidated net profit stood at Rs 112 crore with an EBITDA margin of 9.5%
Standalone revenue increased 23% YoY to Rs 4,548 crore with net profit of Rs 164 crore
Quarterly capex deployed at close to Rs 490 crore to expand capacities, driving up debt
Converted $24.5 million loan to Ceat OHT Lanka into Rs 234 crore equity
👀 What to Watch
Monitor commodity price trends and the management's planned calibrated price hikes in H2 to offset persistent input cost inflation.
Himachal HC Quashes Rs 117.94 Cr GST Demand Show Cause Notice Against Morepen Laboratories
The High Court of Himachal Pradesh has quashed a Show Cause Notice (SCN) issued by the Central GST Commissionerate demanding Rs 117.94 crore in excess GST refund along with interest and penalty. The original demand dated December 2, 2025, represented approximately 83.6% of the company's TTM PAT of Rs 141 crore and 9.5% of its net worth (Rs 1,243 crore). With the writ petition disposed in favour of Morepen Laboratories, the company faces no financial liability or operational disruption from this dispute. The order was passed on October 12, 2026, and received by the company on October 14, 2026.
Confidence: HIGH
What changedThe Himachal Pradesh High Court has fully quashed the Rs 117.94 crore GST recovery show cause notice, deciding the matter entirely in favour of Morepen Laboratories.
Why it mattersA potential tax liability representing over 80% of annual net profit has been removed, eliminating a significant balance sheet and cash flow overhang.
Quashed GST demand: ₹117,94,03,452Demand vs TTM PAT: ~83.6%Demand vs Net Worth: ~9.5%Order date: 12th October 2026Receipt date: 14th October 2026
📅 Short termPositive sentiment driver as an overhang of nearly Rs 118 crore in potential tax clawback is eliminated.
📈 Long termStrengthens financial clarity and protects retained earnings, though investors should ensure no further legal appeals are initiated by tax authorities.
⚠ Risk flags
- Possibility of the GST department challenging the High Court judgment in higher courts (Supreme Court)
Key Highlights
Himachal Pradesh High Court quashed the GST Show Cause Notice demanding recovery of Rs 117,94,03,452
Demand amount of Rs 117.94 crore represents ~83.6% of TTM PAT (Rs 141 crore) and ~6% of TTM revenue (Rs 1,951 crore)
Allegations pertained to excess GST refund claims under Section 54 of CGST Act read with Rule 89(4)
Order passed on October 12, 2026, and formally received by the company on October 14, 2026 at 3:00 p.m.
Company confirmed zero financial, operational, or other adverse impact following the court ruling
👀 What to Watch
Track whether the GST Department files an appeal or Special Leave Petition (SLP) before the Supreme Court against the High Court order, and monitor upcoming Q2 FY27 earnings for core operating performance.
Kesar India Allots 17.32 Lakh Shares at Rs 900 via Share Swap Worth Rs 155.86 Cr
Kesar India Limited has approved the preferential allotment of 17,31,752 equity shares of face value Rs 10 each at an issue price of Rs 900 per share, amounting to Rs 155.86 crore. The allotment is executed for consideration other than cash via a share swap to promoters Yash Gopal Gupta and Sangeeta Gopalchand Gupta (8,65,876 shares each). Following this allotment, the company's paid-up equity share capital increases to Rs 34.27 crore across 3.43 crore shares. The total issuance represents approximately 4.7% of the current market capitalization (Rs 3,318 crore) and will increase promoter holding.
Confidence: HIGH
What changedKesar India expanded its share base by 17.32 lakh shares by issuing equity to promoters via a share swap at Rs 900 per share.
Why it mattersThe Rs 155.86 crore transaction consolidates promoter equity into the listed entity via non-cash asset or share acquisition, expanding the equity base by roughly 5.3% of pre-issue capital.
Shares allotted: 17,31,752Issue price per share: Rs 900Total allotment value: Rs 155.86 CrNew paid-up equity capital: Rs 34,26,59,700Allotment value vs Market Cap: ~4.7%
📅 Short termNeutral market impact expected as the issue price of Rs 900 is at a discount to the current market price of Rs 1,157.30, though it involves no direct cash inflow.
📈 Long termDepends on the operational integration and value accretion of the underlying assets or entities brought into the listed entity through this share swap.
⚠ Risk flags
- Related-party transaction involving promoter entities
- Equity dilution of ~5.1% on expanded equity base without cash inflow
Key Highlights
Allotted 17,31,752 equity shares on a preferential basis for consideration other than cash via share swap
Issue price fixed at Rs 900 per equity share (face value Rs 10 each), totaling Rs 155.86 crore
Allottees are promoters Yash Gopal Gupta (8,65,876 shares) and Sangeeta Gopalchand Gupta (8,65,876 shares)
Paid-up equity capital increased to Rs 34,26,59,700 comprising 3,42,65,970 equity shares
👀 What to Watch
Track subsequent shareholding pattern filings to assess the exact post-issue promoter shareholding percentage and any disclosures regarding the swapped entity/assets.
Mphasis faces revised tax demand of ₹2,417.80 Cr following Section 154 rectification order
Mphasis Limited has received a rectification order under Section 154 of the Income-tax Act, 1961 for Assessment Year 2023-24, increasing its tax demand from ₹2,286.86 crore to ₹2,417.80 crore. The ₹130.94 crore increase is attributable to interest levied under Section 220. The total demand represents approximately 37.3% of the company's net worth (₹6,474 crore) and exceeds its annual TTM PAT of ₹1,911 crore. However, Mphasis noted errors in computation, plans to pursue legal remedies and file a rectification petition, and currently expects no material financial statement impact.
Confidence: HIGH
What changedThe Income Tax department revised an earlier assessment demand for AY 2023-24 upward by ₹130.94 crore to ₹2,417.80 crore via a Section 154 rectification order.
Why it mattersThe quantum of the demand is substantial relative to Mphasis's annual profits (126.5% of TTM PAT) and net worth (37.3%), posing a headline dispute risk even though management expects no material financial statement impact.
Revised tax demand: ₹2,417.80 croreOriginal demand: ₹2,286.86 croreAdditional interest levied: ₹130.94 croreDemand vs TTM PAT: ~126.5%Demand vs Net Worth: ~37.3%
📅 Short termMay weigh on sentiment given the large headline figure, though operational impact depends on the timeline of appeals and stay of demand.
📈 Long termIT sector tax disputes frequently undergo prolonged appellate stages (ITAT/High Court) without immediate cash impairment, but sustained adverse rulings could lead to provisioning.
⚠ Risk flags
- High dispute amount relative to net worth (37.3%) and TTM PAT (126.5%)
- Risk of required pre-deposits during the appeal process
Key Highlights
Tax demand revised upward from ₹2,286.86 crore to ₹2,417.80 crore
Increase of ₹130.94 crore due to interest levied under Section 220 of the Income-tax Act
Order issued on October 9, 2026, and received by the company on October 13, 2026
Company intends to file a rectification petition citing computation errors and seek legal remedies
👀 What to Watch
Track subsequent filings regarding the filing of the rectification petition, appellate proceedings, and whether any pre-deposit or cash outflow is mandated during dispute resolution.
NLC India Secures LoA for 50 MW/200 MWh BESS Project in West Bengal
NLC India Limited's wholly owned subsidiary, NLC India Renewables Limited (NIRL), has won a tender from WBSEDCL for setting up a Standalone Battery Energy Storage System (BESS). The contract awards the development of a 50 MW / 200 MWh capacity BESS located at Arambag, Hooghly, West Bengal under tariff-based competitive bidding. While the exact contract value and capital outlay were not disclosed, this win aligns with the company's stated strategic roadmap to expand beyond thermal power into BESS and renewable integration. Against TTM revenue of ₹18,648 Cr, the project represents an incremental operational foray into grid-scale energy storage.
Confidence: HIGH
What changedNLC India's subsidiary NIRL has received a Letter of Award to build and operate a 50 MW/200 MWh standalone battery storage project in West Bengal.
Why it mattersMarks progress on NLC India's strategic push into non-fossil services and grid-scale storage, complementing its long-term plan to reach 10 GW total capacity.
Storage Power Capacity: 50 MWStorage Energy Capacity: 200 MWhContract Value: not disclosed
📅 Short termPositive sentiment from entry into grid-scale storage contracts; financial impact in the near term will depend on disclosed tariffs and capex.
📈 Long termSupports diversification from lignite/coal generation toward modern renewable-enabling infrastructure, enhancing blended ESG and utility-scale capabilities.
⚠ Risk flags
- Counterparty risk associated with state discom (WBSEDCL)
- Execution and battery component supply-chain risks
- Tariff viability and margins not disclosed
Key Highlights
Subsidiary NIRL secured Letter of Award (LoA) for a 50 MW/200 MWh Standalone BESS project
Project location awarded at Arambag, Hooghly, West Bengal via tariff-based competitive bidding
Tender floated by Dept of Power, GoWB on behalf of WBSEDCL
Commercial project value and commissioning timelines were not disclosed in the filing
👀 What to Watch
Track subsequent disclosures regarding total capex commitment, tariff rate per MW/MWh, and commissioning timelines for this BESS installation.
Q2 FY27 Net Profit Rises 64.9% YoY to ₹70.53 Cr; Revenue Up 26% to ₹326.72 Cr
Bajaj Consumer Care reported standalone revenue from operations of ₹326.72 Cr for Q2 FY27, up 25.9% YoY from ₹259.41 Cr in Q2 FY26. Standalone net profit climbed 64.9% YoY to ₹70.53 Cr compared to ₹42.78 Cr in the corresponding prior-year quarter. For H1 FY27, net profit stood at ₹140.69 Cr on revenues of ₹661.83 Cr. Additionally, the Board appointed FMCG veteran Jitendra Mahajan as Independent Director following the resignation of K.S. Narayanan.
Confidence: HIGH
What changedAnnounced Q2 FY27 earnings showing substantial YoY profit and revenue expansion, along with board reconstitution.
Why it mattersDemonstrates robust operating leverage and top-line recovery compared to FY26 base periods, with net profit margins expanding sharply.
Standalone Revenue (Q2 FY27): ₹32,671.94 lakhStandalone PAT (Q2 FY27): ₹7,052.83 lakhStandalone PAT Growth YoY: 64.9%H1 FY27 PAT: ₹14,068.77 lakh
📅 Short termStrong operational print is likely to be viewed favourably by the market in the coming sessions given the 64.9% YoY net profit growth.
📈 Long termSustained execution across non-ADHO portfolio diversification and brand scaling will determine if margins and growth stay elevated.
⚠ Risk flags
- Input cost volatility (crude oil/LLP packaging) could compress gross margins in upcoming quarters
- High dependence on flagship hair oil category
Key Highlights
Standalone revenue from operations reached ₹32,671.94 lakh (₹326.72 Cr), up 25.9% YoY
Net profit surged 64.9% YoY to ₹7,052.83 lakh (₹70.53 Cr) from ₹4,278.05 lakh in Q2 FY26
Profit before tax grew 68% YoY to ₹8,715.80 lakh compared to ₹5,188.76 lakh
Advertising and sales promotion expenses stood at ₹4,073.55 lakh vs ₹3,808.27 lakh in Q2 FY26
Board approved 5-year appointment of Jitendra Ananda Mahajan as Non-Executive Independent Director
👀 What to Watch
Track subsequent quarters to see if the >20% revenue growth trajectory holds amidst raw material price dynamics and ad-spend investments.
Q2 FY27 Net Sales up 27.3% to ₹332.7 Cr; PAT Surges 66.0% to ₹70.2 Cr
Bajaj Consumer Care reported a strong Q2 FY27 performance, with consolidated net sales increasing 27.3% YoY to ₹332.7 crore. EBITDA jumped 71.0% YoY to ₹83.3 crore, expanding operating margins significantly to 25.0% from 18.6% in Q2 FY26. Consolidated Profit After Tax (PAT) grew 66.0% YoY to ₹70.2 crore, aided by 30%+ revenue growth in domestic hair oils and steady gross margin expansion to 59.9%. For H1 FY27, net sales rose 27.8% YoY to ₹674.1 crore, while PAT climbed 74.8% YoY to ₹140.9 crore.
Confidence: HIGH
What changedFiling of the Q2 FY27 investor presentation following the NCLT-approved amalgamation of Vishal Personal Care Limited.
Why it mattersDemonstrates operating leverage with substantial EBITDA margin expansion (+640 bps YoY) and strong volume-led growth across domestic channels.
Q2 FY27 Net Sales: ₹332.7 CrQ2 FY27 EBITDA Margin: 25.0%Q2 FY27 PAT: ₹70.2 CrH1 FY27 Net Sales: ₹674.1 CrH1 FY27 Net Sales vs FY26 Full Year Revenue: ~57.9%
📅 Short termMarket sentiment is likely to respond positively to the 71% YoY EBITDA growth and strong gross margin resilience despite crude-linked input cost inflation.
📈 Long termThe scaling of non-ADHO portfolio products and network expansion via Project Aarohan (targeting ~60K outlets annually) support long-term revenue diversification.
⚠ Risk flags
- Raw material price inflation in Light Liquid Paraffin (index up to 152) and Copra
- High product concentration in hair oils
Key Highlights
Consolidated Net Sales grew 27.3% YoY to ₹332.7 crore in Q2 FY27
EBITDA increased 71.0% YoY to ₹83.3 crore, with EBITDA margin rising to 25.0% vs 18.6% in Q2 FY26
Consolidated PAT rose 66.0% YoY to ₹70.2 crore
H1 FY27 PAT grew 74.8% YoY to ₹140.9 crore on Net Sales of ₹674.1 crore (+27.8% YoY)
Project Aarohan added 1 Lakh+ retail outlets and 1,100+ distribution partners across three phases
👀 What to Watch
Track whether EBITDA margins sustain near 25% amidst rising raw material cost trends in Light Liquid Paraffin and Copra, and monitor outlet productivity from Aarohan 2.0 in H2 FY27.
Servotech Updates on ₹2.00–₹2.50 Cr Employee Fraud: Two Arrested, ₹75.65 Lakh Recovered
Servotech Renewable Power System provided an update regarding an internal fraud incident initially disclosed on July 23, 2026. The estimated fraud amount remains unchanged at approximately ₹2.00 to ₹2.50 crore, representing about 6-7% of TTM PAT (₹35 crore). Investigating authorities have arrested two employees (Mr. Gagandeep Rajora and Mr. Vijay Kumar) and recovered goods and cheques worth approximately ₹75.65 lakh. The company has appointed an independent forensic auditor to review internal controls and assess the final financial impact.
Confidence: HIGH
What changedTwo employees have been arrested in connection with the suspected internal fraud, and ₹75.65 lakh has been recovered out of the estimated ₹2.00–₹2.50 crore fraud.
Why it mattersWhile the absolute financial exposure (₹2.00–₹2.50 crore) is relatively small compared to TTM revenue of ₹751 crore, it highlights internal control lapses and may result in an earnings provision.
Estimated fraud amount: ₹2.00–₹2.50 croreAmount recovered: Rs.75.65 lakh approx.Fraud vs TTM PAT: ~5.7% to 7.1%Fraud vs TTM revenue: ~0.3%
📅 Short termNegative sentiment regarding governance and internal control mechanisms; potential provision impact in the next quarterly earnings.
📈 Long termLimited direct balance sheet damage given the small quantum, provided forensic audit confirms no deeper systemic fraud or governance breakdown.
⚠ Risk flags
- Internal control failure
- Forensic audit findings could potentially expand the suspected fraud amount
- Unrecovered balance of ~₹1.24–₹1.74 crore
Key Highlights
Estimated fraud amount stands at approximately ₹2.00–₹2.50 crore
Goods and cheques worth approximately ₹75.65 lakh recovered by investigating authorities
Two employees (Gagandeep Rajora and Vijay Kumar) arrested; efforts underway to trace other persons
Independent forensic auditor appointed to review transactions and strengthen internal controls
👀 What to Watch
Track the outcome of the forensic audit report and any write-offs or provisions in upcoming quarterly financial statements.
Q2 FY27 Net Profit Rises 64.9% YoY to ₹70.53 Cr; Revenue Up 26% to ₹326.72 Cr
Bajaj Consumer Care reported standalone revenue from operations of ₹326.72 Cr for Q2 FY27, up 25.9% YoY from ₹259.41 Cr in Q2 FY26. Standalone net profit climbed 64.9% YoY to ₹70.53 Cr compared to ₹42.78 Cr in the corresponding prior-year quarter. For H1 FY27, net profit stood at ₹140.69 Cr on revenues of ₹661.83 Cr. Additionally, the Board appointed FMCG veteran Jitendra Mahajan as Independent Director following the resignation of K.S. Narayanan.
Confidence: HIGH
What changedAnnounced Q2 FY27 earnings showing substantial YoY profit and revenue expansion, along with board reconstitution.
Why it mattersDemonstrates robust operating leverage and top-line recovery compared to FY26 base periods, with net profit margins expanding sharply.
Standalone Revenue (Q2 FY27): ₹32,671.94 lakhStandalone PAT (Q2 FY27): ₹7,052.83 lakhStandalone PAT Growth YoY: 64.9%H1 FY27 PAT: ₹14,068.77 lakh
📅 Short termStrong operational print is likely to be viewed favourably by the market in the coming sessions given the 64.9% YoY net profit growth.
📈 Long termSustained execution across non-ADHO portfolio diversification and brand scaling will determine if margins and growth stay elevated.
⚠ Risk flags
- Input cost volatility (crude oil/LLP packaging) could compress gross margins in upcoming quarters
- High dependence on flagship hair oil category
Key Highlights
Standalone revenue from operations reached ₹32,671.94 lakh (₹326.72 Cr), up 25.9% YoY
Net profit surged 64.9% YoY to ₹7,052.83 lakh (₹70.53 Cr) from ₹4,278.05 lakh in Q2 FY26
Profit before tax grew 68% YoY to ₹8,715.80 lakh compared to ₹5,188.76 lakh
Advertising and sales promotion expenses stood at ₹4,073.55 lakh vs ₹3,808.27 lakh in Q2 FY26
Board approved 5-year appointment of Jitendra Ananda Mahajan as Non-Executive Independent Director
👀 What to Watch
Track subsequent quarters to see if the >20% revenue growth trajectory holds amidst raw material price dynamics and ad-spend investments.
Brooks Labs Approves Demerger of Manufacturing Business into Abridge Speciality in 1:1 Ratio
Brooks Laboratories has approved a Scheme of Arrangement to demerge its Baddi manufacturing business into its wholly-owned subsidiary, Abridge Speciality Limited. The demerged undertaking accounted for Rs 82.87 crore (96.66%) of the company's FY26 total turnover. Under the scheme, shareholders will receive 1 share of Abridge Speciality for every 1 share held in Brooks Laboratories, with listing intended for the resulting entity on BSE and NSE. The residual business will focus on trading and be renamed Xuri Lifesciences, while Abridge Speciality will adopt the Brooks Laboratories name.
Confidence: HIGH
What changedBoard approved demerging the core Baddi manufacturing operations into wholly-owned subsidiary Abridge Speciality Limited via a 1:1 vertical split.
Why it mattersSeparates the manufacturing unit (96.66% of FY26 revenue) from the trading business to facilitate independent management, targeted capital allocation, and aligned promoter ownership.
Demerged Unit FY26 Turnover: Rs. 8,287.26 lakhsShare of Demerged Turnover in Total: 96.66%Share Entitlement Ratio: 1:1Shares to be Allotted by Resulting Co: 2,94,57,248Indicative Timeline to Listing: About 16 months
📅 Short termMarket may view the 1:1 demerger positively due to clear segregation of core manufacturing, though price action may be balanced by the lengthy execution timeline.
📈 Long termCreates two distinct listed entities; unlocks potential value if the demerged manufacturing entity scales and achieves independent financing and operational focus.
⚠ Risk flags
- Lengthy restructuring timeline (~16 months) requiring NCLT, SEBI, exchange, and creditor approvals
- Demerged entity takes 96.66% of revenue, leaving the residual company with a very small initial turnover base
Key Highlights
Demerged business accounted for Rs 82.87 crore or 96.66% of FY26 total turnover
Share entitlement ratio approved at 1:1 (one share of Abridge Speciality for each share of Brooks Labs)
Abridge Speciality will issue 2,94,57,248 equity shares and seek listing on BSE and NSE
Estimated timeline to final listing is approximately 16 months across 4 stages
Expected capital availability of ~Rs 50 crore planned for strategic growth in each platform
👀 What to Watch
Track the regulatory progress over the next 6 months, specifically stock exchange approvals and the filing of the first-motion petition before the NCLT.
Sonaselection Q1 FY27 Standalone PAT at ₹9.65 Cr; Revenue Up 39.8% YoY to ₹145.75 Cr
Sonaselection India Limited reported standalone revenue from operations of ₹145.75 crore for Q1 ended June 30, 2026, marking a 39.8% YoY increase compared to ₹104.24 crore in Q1 FY26. Standalone Profit After Tax (PAT) doubled to ₹9.65 crore from ₹4.80 crore in the year-ago quarter, with Basic EPS at ₹2.28. Notably, profit was aided by a change in accounting estimate for asset useful lives, which reduced quarterly depreciation by ₹1.73 crore and increased PAT by ₹1.22 crore. Consolidated revenue stood at ₹145.75+ crore with a consolidated PAT of ₹9.75 crore.
Confidence: HIGH
What changedSonaselection India reported its un-audited Q1 FY27 financial results post-listing and revised the useful life of plant, machinery, and solar assets from 15 to 25 years.
Why it mattersDemonstrates strong top-line and operational earnings growth, though reported net margins are partially boosted by lower depreciation from accounting adjustments.
Standalone Revenue (Q1): 145.75Standalone PAT (Q1): 9.65Consolidated PAT (Q1): 9.75Depreciation reduction benefit: 1.73PAT boost from depreciation revision: 1.22
📅 Short termMarket may react positively to the strong reported growth in revenue and PAT, though discerning investors will adjust for the ₹1.22 crore accounting gain.
📈 Long termExpansion of operational scale following its IPO is key to sustaining margin performance, alongside efficient integration of subsidiary Sionnah Enterprises.
⚠ Risk flags
- Change in depreciation accounting estimate artificially inflates reported profitability by ₹1.22 crore
- Material consumption and inventory swings were substantial during the quarter
Key Highlights
Standalone revenue from operations grew 39.8% YoY to ₹145.75 crore versus ₹104.24 crore in Q1 FY26
Standalone Profit After Tax increased 101% YoY to ₹9.65 crore compared to ₹4.80 crore in Q1 FY26
Consolidated PAT stood at ₹9.75 crore with a Basic EPS of ₹2.30
Revision in useful lives of plant, machinery, and solar assets reduced depreciation by ₹1.73 crore, boosting PAT by ₹1.22 crore
👀 What to Watch
Track operating margins excluding the accounting policy change impact and monitor subsequent Q2 results for demand sustainability in the textile segment.
Indian Phosphate Reports Q2 FY27 Consolidated Revenue Up 83.8% YoY to ₹450.2 Cr
Indian Phosphate Limited released its Q2 FY27 business update, highlighting an 83.78% YoY surge in consolidated revenue to ₹45,020.71 Lakhs (₹450.21 Cr) compared to ₹24,496.84 Lakhs in Q2 FY26. For H1 FY27, consolidated revenue increased 82.38% YoY to ₹91,030.66 Lakhs (₹910.31 Cr), representing approximately 46.4% of its TTM revenue (₹1,963 Cr). Growth was driven by the commercial ramp-up of the Cuddalore unit, including a 100 MT/day Anionic Surfactant plant commissioned in June 2026, alongside entry into potassic fertilizers under an arrangement with K+S Middle East.
Confidence: HIGH
What changedIndian Phosphate released its Q2 FY27 business update showing an 83.8% jump in quarterly consolidated top-line following new capacity commercialization at Cuddalore.
Why it mattersThe ramp-up of the 100 MT/day anionic surfactant unit and new SOP fertilizer distribution validate the company's geographical and product diversification beyond its traditional SSP fertilizer base.
Q2 FY27 Consolidated Revenue: ₹45,020.71 LakhsQ2 FY27 Standalone Revenue Growth: 94.39%H1 FY27 Consolidated Revenue: ₹91,030.66 LakhsAnionic Surfactant Capacity: 100 MT/dayH1 FY27 Revenue vs TTM Revenue: ~46.4%
📅 Short termMarket sentiment should react positively to strong operational top-line momentum, though investors will await detailed profit margins in the audited/reviewed quarterly filing.
📈 Long termDiversifying into chemical surfactants and high-value potassic fertilizers helps insulate the company from government-regulated SSP subsidy regimes and expands its presence in South India.
⚠ Risk flags
- Profitability figures not disclosed in the update; top-line surge might face raw material cost inflation (LABSA inputs)
- Sri Lanka Eppawala rock phosphate value-addition project is still under government evaluation
Key Highlights
Q2 FY27 consolidated revenue surged 83.78% YoY to ₹45,020.71 Lakhs from ₹24,496.84 Lakhs
H1 FY27 consolidated revenue reached ₹91,030.66 Lakhs, growing 82.38% YoY
Commercial production of the Anionic Surfactant plant at Cuddalore commenced in June 2026 with a 100 MT/day capacity
Brickwork Ratings assigned a credit rating of BWR A-/Stable (fund based) and BWR A2+ (non-fund based) in June 2026
👀 What to Watch
Track the upcoming full Q2 FY27 financial results for margin performance, as well as regulatory updates on the Sri Lanka rock phosphate concession proposal.
Nidhi Granites to Acquire 50.50% Stake in Jowela Exim for ₹1.60 Cr via Rights Issue
Nidhi Granites has approved subscribing to the rights issue of Jowela Exim Private Limited for ₹1.60 crore (16,00,000 equity shares at ₹10 each). Following the allotment, Nidhi Granites will hold a 50.50% controlling stake (16,16,000 shares), making Jowela Exim a subsidiary. Jowela operates in precious metals, diamond-studded jewelry, and bullion, reporting a FY26 turnover of ₹743.54 crore—dwarfing Nidhi Granites' FY26 revenue of ₹65.2 crore. The transaction is expected to be completed by end of October 2026.
Confidence: HIGH
What changedNidhi Granites is investing ₹1.60 crore to gain a 50.50% controlling interest in Jowela Exim, converting it into a subsidiary.
Why it mattersThe target company reported a massive turnover of ₹743.54 crore compared to Nidhi's ₹65.2 crore FY26 revenue, which could fundamentally transform Nidhi Granites' consolidated scale and profile.
Investment consideration: ₹1,60,00,000Stake acquired: 50.50%Jowela Exim FY26 turnover: INR 7,43,53,81,801.86Target turnover vs Company TTM revenue: ~1219%
📅 Short termThe stock is likely to see heightened market attention given the outsized revenue scale of the acquired entity relative to the ₹1.60 crore acquisition price.
📈 Long termIf successfully consolidated, Jowela Exim shifts Nidhi Granites significantly toward precious metals and jewelry trading; however, profitability, balance sheet leverage, and integration remain critical monitorables.
⚠ Risk flags
- Divergence in business lines moving further away from core into low-margin precious metals/gems trading
- Extremely large target revenue (₹743.54 Cr) acquired for merely ₹1.60 Cr warrants scrutiny of target debt, net margins, and liabilities
Key Highlights
Subscribing to 16,00,000 shares at ₹10 each for a total consideration of ₹1,60,00,000
Post-allotment holding will increase to 16,16,000 equity shares or 50.50% controlling stake
Target entity Jowela Exim reported FY26 turnover of ₹7,43,53,81,801.86
Acquisition scheduled for completion by end of October 2026 with no material regulatory approvals required
👀 What to Watch
Track the completion of share allotment by late October 2026 and look for consolidated financial reporting in subsequent quarters to evaluate the profitability, working capital needs, and margins of Jowela Exim.
Pro Clb Global Appoints Het Kalpeshkumar Shah as CEO Effective Oct 14, 2026
Pro Clb Global Limited has approved the appointment of existing director Mr. Het Kalpeshkumar Shah (28 years old) as Chief Executive Officer, effective October 14, 2026. Mr. Shah will continue holding his position as a Director while taking on the additional CEO responsibilities. The micro-cap consulting firm operates with a market cap of approximately ₹22 crore, TTM revenue of ₹1 crore, and notably has 0.0% promoter holding as of June 2026.
Confidence: HIGH
What changedExisting Director Mr. Het Kalpeshkumar Shah has been appointed as the Chief Executive Officer effective October 14, 2026.
Why it mattersDesignates primary executive leadership for this micro-cap consulting firm (TTM revenue ₹1 crore) with nil promoter shareholding.
Appointee Age: 28 years oldEffective Date: 14.10.2026Promoter Holding: 0.0%TTM Revenue: ₹1 Cr
📅 Short termLimited near-term stock reaction expected as the appointment represents an internal elevation to the CEO position.
📈 Long termGiven the micro-cap size and complete absence of promoter holding, long-term performance hinges on executive capability to drive revenue expansion beyond current ₹1 crore TTM scale.
⚠ Risk flags
- 0.0% promoter holding indicates absence of skin in the game by founders
- Extremely small revenue base (₹1 Cr TTM) leading to high quarterly earnings volatility
Key Highlights
Appointment of Mr. Het Kalpeshkumar Shah (DIN: 11460553) as Chief Executive Officer approved on 14th October, 2026
Mr. Shah is 28 years old and already serves as an existing Director of the company
Disclosure confirms Mr. Shah is not related to any other director on the board
👀 What to Watch
Track upcoming quarterly financial disclosures to see if strategic direction or revenue scale shifts under the new leadership.
HEC Infra Wins Rs 6.75 Cr Work Order from CESC Limited
HEC Infra Projects Limited has secured a domestic work order worth Rs 6.75 crore from CESC Limited. The contract entails the supply of 2 units of 20 MVA 33/11-6 KV Power transformers. The execution timeline for the project is 6 months from the date of award. This contract is not a related-party transaction and reflects continued traction in the company's power transmission business.
Confidence: HIGH
What changedAwarded a new Rs 6.75 crore equipment supply contract from private power utility CESC Limited.
Why it mattersAdds revenue visibility for the next two quarters and supports the company's track record in bidding for private utility transformer contracts.
Order value: Rs.6.75 croresExecution period: 6 monthsUnits to supply: 2 nos 20 MVA 33/11-6 KV Power transformerOrder vs Net worth: ~10.2% (Rs 6.75 Cr / Rs 66 Cr)
📅 Short termProvides positive sentiment with immediate additions to the operational backlog, scheduled to convert to revenue within six months.
📈 Long termLimited in scale on a standalone basis, but strengthens credentials for future private and state power transmission tenders.
⚠ Risk flags
- Tight 6-month delivery timeline exposed to supply chain or manufacturing bottlenecks
Key Highlights
Received work order valued at Rs 6.75 crores
Contract awarded by domestic utility CESC Limited
Scope covers supply of 2 nos 20 MVA 33/11-6 KV Power transformers
Stipulated execution timeline of 6 months
👀 What to Watch
Track timely delivery within the 6-month window and watch for margin performance and revenue recognition in upcoming quarterly earnings reports.
Open offer launched to acquire 26% of Avishkar Infra Realty at Rs 23 per share
Aftertrade Broking submitted a Public Announcement on behalf of acquirer Nalin Ramaniklal Shah along with 10 Persons Acting in Concert (PACs) to acquire up to 58,24,853 shares of Avishkar Infra Realty Ltd. The offer represents 26% of the target company's total voting share capital under SEBI SAST Regulations. The open offer price is fixed at Rs 23 per share, representing an aggregate offer size of approximately Rs 13.40 crore. Notably, the offer price of Rs 23 is at a substantial discount of ~96% to the current market price of Rs 567.20.
Confidence: HIGH
What changedNalin Ramaniklal Shah and PACs have triggered an open offer to acquire a 26% stake in Avishkar Infra Realty under SEBI SAST Regulations 3(1) and 4.
Why it mattersA change in control or substantial acquisition could reshape operations for the company, which reported Rs 0 TTM revenue and a Rs 2 crore TTM loss. However, the offer price of Rs 23 is drastically lower than the prevailing market price of Rs 567.20.
Offer shares: 58,24,853Share capital percentage: 26%Offer price per share: Rs. 23/-Total offer value: Rs 13.40 CrDiscount to current price (Rs 567.2): ~96%
📅 Short termGiven the massive discount of the Rs 23 offer price against the trading price of Rs 567.20, public shareholder tendering acceptance may remain limited unless secondary prices adjust.
📈 Long termPotential change of ownership could alter the operational trajectory of the firm, which has experienced stagnant zero revenues across recent quarters.
⚠ Risk flags
- Severe divergence between offer price (Rs 23) and market price (Rs 567.20).
- Company fundamentals reflect zero TTM revenue and ongoing net losses.
Key Highlights
Open offer to acquire up to 58,24,853 equity shares of Avishkar Infra Realty Ltd.
Offer represents exactly 26% of the company's Total Voting Share Capital.
Offer price set at Rs 23 per equity share.
Offer is made by Nalin Ramaniklal Shah alongside 10 Persons Acting in Concert (PACs).
👀 What to Watch
Track the upcoming Detailed Public Statement (DPS) and Letter of Offer for the underlying transaction triggers, management control intentions, and regulatory tendering timelines.
Arham Technologies Receives In-Principle NSE Approval to Migrate 2.18 Cr Shares to Main Board
Arham Technologies has received in-principle approval from the NSE to migrate its 2,18,12,000 equity shares (face value Rs 10 each) from the SME Platform (EMERGE) to the Main Board. The approval, dated October 14, 2026, is valid for 45 days. The company must now submit its listing application and listing agreement to obtain final approval from the Exchange. Migration to the main board provides higher trading liquidity and broader institutional access compared to the SME segment.
Confidence: HIGH
What changedNSE approved Arham Technologies' in-principle request to migrate trading of its equity shares from the EMERGE SME platform to the Main Board.
Why it mattersMigration removes SME-specific lot size trading constraints, potentially increasing retail and institutional participation, trading volume, and liquidity.
Shares eligible for migration: 21812000Face value per share: Rs. 10Approval validity: 45 daysLetter issue date: October 14, 2026
📅 Short termFormalities such as submitting listing documentation will proceed over the next 45 days ahead of final listing notification.
📈 Long termMain board listing offers improved corporate visibility, greater analyst coverage, and easier institutional capital access to support its planned growth.
⚠ Risk flags
- Approval withdrawal risk if submitted information is found incomplete or non-compliant
- Failure to meet listing conditions within the 45-day validity window
Key Highlights
NSE granted in-principle approval on October 14, 2026, via letter NSE/LIST/311
Covers migration of 2,18,12,000 equity shares of Rs 10 face value from SME (EMERGE) to Main Board
In-principle approval validity is 45 days from the date of issuance
Final approval remains subject to filing the listing application and equity listing agreement
👀 What to Watch
Track the submission of the final listing application within the 45-day window and watch for the NSE circular announcing the effective date of Main Board trading.
